Harvard Health Blog

PCSK9 inhibitors: a major advance in cholesterol-lowering drug therapy

Posted March 15, 2015, 11:02 am, Updated March 20, 2015, 12:22 pm Gregory Curfman, M.D., Editor in Chief, Harvard Health Publications Every so often a medical advance comes along that rewrites the script for treating a disease or condition. After today’s announcements of impressive results of a new type of cholesterol-lowering drug, that scenario just might happen in the next few years. …

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In